Document:

EX-4.16:

 

Exhibit 4.16

	 	 	 
	

	 	
	«FirstName»
«LastName»
	 	 
	«Address 1»

	 	December 31, 2004
	Country
	 	 

Conversion of Aventis Stock Option Plans (including former Hoechst, RP and RPR
Plans)

Dear «FirstName»,

This letter explains the effect of the legal merger of Aventis with and into
sanofi-aventis, effective December 31, 2004 on your Aventis Stock Options
including the former Hoechst, RP and RPR Plans.

Your options have been converted to sanofi-aventis options, based on the same
exchange ratio (27 sanofi-aventis stock options for 23 Aventis stock options)
applied to the shareholders. As a result the number of your Aventis options and
the grant price have been adjusted according to this ratio to reflect the
adequate value before and after the conversion (please find attached your
personal conversion letter).

All other terms and conditions of the Aventis Stock Option Plans (including the
former Hoechst, RP and RPR Plans) remain in effect and are incorporated by
sanofi-aventis.

The following example illustrates the details of the applied conversion
regulations:

	 	 	 
	What:

	 	conversion of the Aventis stock options into sanofi-aventis stock options
	How:

	 	conversion of stock option with merger ratio *27/23 (rounded down to next full number)
	

	 	conversion of grant price with merger ratio *23/27(rounded down to next second decimal place)
	Example:

	 	Aventis SOP 2002

	 	 	 	 	 	 	 	 	 
	 	 	Prior to adaptation	 	After adaptation
	Grant Price

	 	 	60,27 €	 	 	 	51,34 €	 
	Number of Options

	 	 	100	 	 	 	117	 

If you have any questions, please call the Call Center of our stock option
administrator Citigroup (see phone numbers below).

Sincerely,

Heike König

Corporate Compensation

Enclosure:

Personal Conversion Statement

	 	 	 
	San Antonio, Texas
	 	 
	optionees located in North America and Canada please call:

	 	1 (866) 919 1 AVE (283)
	optionees located in South and Latin America please call:

	 	+ (1) 212 615 7965 Monday
– Friday, 8 a.m. – 6 p.m. (EST)
	 
	 	 
	Barcelona, Spain
	 	 
	optionees located in Europe, Middle East and Africa please call:

	 	+ (800) 919 9000 or
	

	 	+ (34) 93 316 5938 Monday
– Friday, 8 a.m. – 6 p.m. (CET)
	 
	 	 
	Brisbane, Australia
	 	 
	Optionees located in Australia please call:

	 	1 (800) 00 2484
	Optionees located in the Asia/Pacific Region please call:

	 	+ (800) 0000 2484 Monday
– Friday, 9 a.m. – 8 p.m. (Sydney)EX-4.17:

 

Exhibit 4.17

			
	«FirstName» «LastName»

«Address1»
	 	
	Country	 	 

December 31, 2004

Conversion of Aventis Stock Option Plans (including former Hoechst, RP and RPR Plans)

Dear «FirstName»,

This letter explains the effect of the legal merger of Aventis with and into sanofi-aventis,
effective December 31, 2004 on your Aventis Stock Options including the former Hoechst, RP and RPR
Plans.

Your options have been converted to sanofi-aventis options, based on the same exchange ratio (27
sanofi-aventis stock options for 23 Aventis stock options) applied to the shareholders. As a result
the number of your Aventis options and the grant price have been adjusted according to this ratio
to reflect the adequate value before and after the conversion (please find attached your personal
conversion statement).

The following example illustrates the details of the applied conversion regulations:

	 	 	 
	What:

	 	conversion of the Aventis stock options into sanofi-aventis stock options
	How:

	 	conversion of stock option with merger ratio *27/23 (rounded down to next full number)

conversion of grant price with merger ratio *23/27(rounded down to next second decimal place)
	Example:

	 	Aventis SOP 2002

	 	 	 	 	 
	 	 	Prior to adaptation	 	After adaptation
	Grant Price
	 	60,27 €	 	51,34 €
	Number of Options
	 	100	 	117

All other terms and conditions of the Aventis Stock Option Plans (including the former
Hoechst, RP and RPR Plans) remain in effect and are incorporated by sanofi-aventis.

If you have any questions, please call the Call Center of our stock option administrator

Société Générale, + 33 2 51 85 67 89.

Sincerely,

Heike König

Corporate Compensation

Enclosure:

Personal Conversion StatementEX-4.18:

 

Exhibit 4.18

Stock-option Plans
issued by Aventis Inc.

Amendment to the Plan rules effective on December 31st 2004

     Aventis Inc., formerly known as Rhone-Poulenc Rorer Inc., issued several grants of options to
purchase Rhone-Poulenc Rorer shares in 1995, 1996 and 1997 pursuant to the Rorer Group Equity
Compensation Plan, effective on March 11, 1990, the Rhone-Poulenc-Rorer Equity Compensation Plan,
effective on May 1, 1995, and the 1995 Rhone-Poulenc-Rorer Equity Compensation Plan, as Amended and
Restated effective on November 1, 1996 (collectively, the “RPR Plans”).

     As of December 20, 2004, there remain outstanding unexercised options awarded to holders
pursuant to grants issued on the dates and at the exercise prices set out below:

     February 27, 1995 at an exercise price of US $ 40.00 per RPR share

     February 27, 1996 at an exercise price of US $ 64.00 per RPR share

     February 20, 1997 at an exercise price of US $ 73.62 per RPR share.

     On the date of the grants indicated above, each purchase stock option awarded under these plans
gave the right to purchase one share of Rhone-Poulenc Rorer Inc., which shares were at that time
listed on the New York Stock Exchange.

     On December 1, 1997, Rhone-Poulenc SA completed a public exchange offer for the outstanding
shares of Rhone-Poulenc Rorer Inc., as a result of which the Rhone-Poulenc Rorer Inc. shares were
delisted from the New York Stock Exchange.

     At that date, the rules of the RPR Plans were amended in order to convert the outstanding
options to purchase Rhone-Poulenc Rorer Inc shares into options to purchase American depositary
shares of Rhone-Poulenc (each a “R-P ADS”). The conversion was made by multiplying the number of
Rhone-Poulenc Rorer options awarded under each grant by 2.4 and dividing the respective exercise
prices by 2.4.

     As a result, after giving effect to the conversion, each option resulting from the grants
listed above had the following adjusted exercise price:

     February 27, 1995 grant: exercise price of US $16.67 per R-P ADS

     February 27, 1996 grant: exercise price of US $26.67 per R-P ADS

     February 20, 1997 grant: exercise price of US $30.68 per R-P ADS

     On December 15, 1999, in connection with its business combination with Hoechst AG,
Rhone-Poulenc SA changed its name to Aventis and the R-P ADSs were renamed “Aventis ADSs”. The
business combination with Hoechst did not give rise to any adjustments to the purchase stock
options awarded under the RPR Plans, as previously adjusted to give effect to the Rhone-Poulenc
Rorer Inc exchange offer described above.

     On October 14, 2004, Sanofi-Aventis, a French société anonyme, and Aventis, entered into an
Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things,
Aventis will merge with and into Sanofi-Aventis (the “Merger”). As a result of the Merger,
Sanofi-Aventis will continue as the surviving company, Aventis will be dissolved and the
shareholders of Aventis (other than Aventis and Sanofi-Aventis) will receive 27 Sanofi-Aventis
ordinary shares, nominal value €2 per share, for every 23 Aventis ordinary shares, nominal value
€3.82 per share, that they hold (such ratio, the “Merger Exchange Ratio”). For legal purposes, the
Merger Agreement provides that the Merger will be effective as of December 31, 2004.

 

 

     The Merger Agreement provides that Sanofi-Aventis shall cause the regulations of the RPR Plans
to be amended to provide that, after the effective time of the Merger, holders of purchase options
granted under the RPR Plans will have the right to purchase Sanofi-Aventis shares, after adjusting
the purchase price and the number of shares subject to option to give effect to the Merger Exchange
Ratio, with all other terms of exercise remaining unaltered. Because purchase options granted
under the RPR Plans give the right to purchase Aventis ADSs (formerly known as R-P ADSs) the
adjusted purchase options, after giving effect to the Merger Exchange Ratio, will give the right to
acquire Sanofi-Aventis ADSs, each Sanofi-Aventis ADS representing one-half of one Sanofi-Aventis
share.

     Accordingly, subject to the effectiveness of the Merger, the rules and regulations of the
Hoechst Plan are hereby amended and the outstanding options, as of the effective time of the Merger
on December 31, 2004, are converted into options to purchase Sanofi-Aventis ordinary shares,
subject to the following adjustments to give effect to the Merger Exchange Ratio and to the fact
that one Sanofi-Aventis share is represented by two Sanofi-Aventis ADS (the “ADS Ratio”):

	 	•	 	the number of existing options shall be multiplied by the Merger Exchange Ratio of
27/23 (or approximately 1.17391) and then multiplied by the ADS Ratio of 2, with the
result rounded down to the nearest whole number; and

	 	•	 	the existing exercise price shall be divided by the Merger Exchange Ratio of 27/23 (or
approximately 1.17391) and then divided by the ADS Ratio of 2, with the result rounded
down to the nearest whole U.S. cent.

     All other terms of exercise shall remain unaltered.

     As a result, after giving effect to the conversion, each option resulting from the grants
under the RPR Plans listed above shall the following adjusted exercise prices:

     February 27,
1995 grant: exercise price of US $7.10 per one Sanofi-Aventis
ADS

     February 27, 1996 grant: exercise price of US $11.35 per one Sanofi-Aventis ADS

     February 20, 1997 grant: exercise price of US $13.06 per one Sanofi-Aventis ADS.EX-4.19:

 

Exhibit 4.19

Amendment to the Stock Option Continuity Plan 1999

     It is recalled that this Stock Option Continuity Plan, referred to herein as the “Hoechst
Plan”, was issued on September 7, 1999 by Hoechst A.G.

     On December 15, 1999, the effective date of the exchange of Hoechst shares for Aventis shares
pursuant to the terms and conditions of the public exchange offer made by Aventis (formerly known
as Rhône-Poulenc S.A.) for Hoechst (the “Public Exchange Offer”), the Hoechst Plan rules were
amended in order to convert outstanding purchase options granted under such Hoechst Plan into
options to purchase Aventis shares, after adjusting the terms to give effect to the same exchange
ratio as applied in the Public Exchange Offer.

     After such conversion, each converted purchase option gave the right to purchase one Aventis
share at an exercise price of 48.43 euros per Aventis share.

     On October 14, 2004, Sanofi-Aventis, a French société anonyme, and Aventis, entered into an
Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things,
Aventis will merge with and into Sanofi-Aventis (the “Merger”). As a result of the Merger,
Sanofi-Aventis will continue as the surviving company, Aventis will be dissolved and the
shareholders of Aventis (other than Aventis and Sanofi-Aventis) will receive 27 Sanofi-Aventis
ordinary shares, nominal value €2 per share, for every 23 Aventis ordinary shares, nominal value
€3.82 per share, that they hold (such ratio, the “Merger Exchange Ratio”). For legal purposes, the
Merger Agreement provides that the Merger will be effective as of December 31, 2004.

     The Merger Agreement provides that Sanofi-Aventis shall cause the regulations of the Hoechst
Plan to be amended to provide that, after the effective time of the Merger, holders of purchase
options granted under the Hoechst Plan will have the right to purchase Sanofi-Aventis shares, after
adjusting the purchase price and the number of shares subject to option to give effect to the
Merger Exchange Ratio, with all other terms of exercise remaining unaltered.

     Accordingly, subject to the effectiveness of the Merger, the rules and regulations of the
Hoechst Plan are hereby amended and the outstanding options, as of the effective time of the Merger
on December 31, 2004, are converted into options to purchase Sanofi-Aventis ordinary shares,
subject to the following adjustments to give effect to the Merger Exchange Ratio:

	 	•	 	the number of existing options shall be multiplied by the Merger Exchange Ratio of
27/23 (or approximately 1.17391) and rounded down to the nearest whole number; and
	 
	 	•	 	the existing exercise price shall be divided by the Merger Exchange Ratio of 27/23 (or
approximately 1.17391) and rounded down to the nearest whole euro
centime.

All other terms of exercise shall remain unaltered.

     As a result, the converted exercise price of an option granted under the Hoechst Plan on
September 7, 1999 will be 41.25 euros and shall entitle the holder to purchase ONE Sanofi-Aventis
ordinary share.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]